HCW Biologics shares surge 11.60% premarket after securing $7M upfront license fee for HCW11-006 with equity and Americas rights option.

HCW Biologics surged 11.6% in premarket trading following the announcement of a $7.0 million upfront payment from Beijing Trimmune Biotech for an exclusive global license of HCW11-006, a fusion immunotherapeutic. The payment included $3.5 million in cash and $3.5 million in transferable equity, with potential future milestone payments, royalties, and a "free" option to reclaim rights to the Americas post-China Phase 1 trials. The deal advances HCW11-006’s development while securing non-dilutive funding, and Trimmune’s backing by major investors like CITIC Medical Fund and TigerMed adds credibility to the partnership. The strategic flexibility to retain U.S. rights and the licensing structure’s upside potential likely fueled the sharp premarket rally.